Related references
Note: Only part of the references are listed.Five Years of GWAS Discovery
Peter M. Visscher et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2012)
Chemoprevention in familial adenomatous polyposis
Brian Kim et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2011)
A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis
John Burn et al.
CANCER PREVENTION RESEARCH (2011)
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials
Peter M. Rothwell et al.
LANCET (2011)
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials
Peter M. Rothwell et al.
LANCET (2010)
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
RS Bresalier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention
SD Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A randomized trial of aspirin to prevent colorectal adenomas
JA Baron et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer
RS Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
G Steinbach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
